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weveral breaking trials in the field of interventional
ardiology were presented at the 33rd annual
cientific session of the Society for Cardiovascular
ngiography and Interventions (SCAI) held in
an Diego, California, May 5 to 8, 2010, and at
uroPCR 2010, held in Paris, France, May 25 to
8, 2010. A brief overview of key results is pre-
ented here.
-Year Interim Results of the Zilver
eripheral Paclitaxel-Eluting Stent (PES)
his single-arm registry (completed outside the
.S.) included 787 patients with symptomatic
isease of femoropopliteal arteries with a reference
essel diameter of 4 to 9 mm treated with the
ilver polymer-free peripheral arterial PES (Cook
edical, Bloomington, Indiana) (1). A total of 900
esions were treated: with a mean lesion length of
00  82 mm, 38% total occlusions, and 28%
estenotic lesions; on average, 1.9 stents were used
er lesion. The primary end points were safety
event-free survival and freedom from procedure-
r device-related mortality or amputation), stent
ntegrity (freedom from device-related morbidity
r complications), and effectiveness (freedom from
linically driven target lesion revascularization
TLR]). At 2-year follow-up, which was com-
leted for 451 patients, event-free survival was
0%, with no device-related deaths, but with 4
rocedure-related deaths (0.9%) and 1 amputation
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ll other authors report that they have no relationships to disclose.0.2%). In 2 years, 81 patients (18%) underwent
linically driven TLR, and 2 patients (0.4%) had a
orsening Rutherford classification. Of the total
,432 stents implanted in the study (maximum of 4
tents/patient), there were 22 fractures (1.5%), of
hich 14 caused displacement of segments of the
tent.
Although these interim results sound promising
or a drug-eluting stent in the peripheral vascula-
ure, confirmation will arrive only with future
andomized studies with longer follow-up. The
nherent limitations of this single-arm study (no
ontrol group) will be addressed in the ongoing,
80-patient randomized controlled trial compar-
ng the same peripheral arterial PES to balloon
ngioplasty followed up to 5 years. Although
pproved in Europe, the Zilver PES is still
waiting approval by the Federal Drug Admin-
stration (FDA) in the U.S.
he EVEREST II Update
he EVEREST II (Endovascular Valve Edge-to-
dge REpair STudy II) (2) randomized 2:1 a total
f 279 patients with moderate to severe (3) or
evere (4) mitral regurgitation (MR) (3) to either
ercutaneous mitral valve repair (n 184) with the
itraClip device (Abbott, Abbott Park, Illinois) or
urgical repair/replacement (n  95). Primary end
oints of the study were major adverse events at 30
ays and clinical success rate, defined as freedom
rom a combination of death, mitral valve surgery
r reoperation for mitral valve dysfunction, and
R grade 2 at 12 months. Preliminary 2-year
aplan-Meier estimates of freedom of reoperation
in the control arm) or first mitral valve operation
in the device arm) on an intention-to-treat basis
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883atients were presented according to MR etiology (degen-
rative [n  135] or functional [n  49]). Patients with
unctional MR significantly more often had coronary artery
isease and prior coronary artery bypass surgery compared
ith patients with degenerative MR. The 30-day modified
ajor adverse event rates were comparable for patients with
egenerative (8.1%) and functional (8.2%) MR; reduction of
R severity to 1/2 at 12-month follow-up was similar
or degenerative (82.8%) and functional (78.1%) MR pa-
ients; and the improvement in New York Heart Associa-
ion functional classification to I/II at 12 months was equal
n degenerative (97.8%) and functional (96.7%) MR pa-
ients.
The favorable results of this study offer the MitraClip
rocedure as a reasonable percutaneous option for selected
atients with significant mitral regurgitation compared with
urgery. However, the device is awaiting approval in the
.S. by the FDA, and although already approved in Europe,
ill require a learning curve by operators prior to replicating
hese results.
he RESOLUTE III Trial
he RESOLUTE III trial (4) was a large-scale comparison
f 2 drug-eluting stents powered to detect noninferiority in
he primary end point of target lesion failure (TLF) (defined
s cardiac death, myocardial infarction attributable to the
arget vessel, and clinically driven TLR). A total of 2,300
atients were randomized in this all-comer trial to treat-
ent with the Endeavor Resolute zotarolimus-eluting stent
ZES) (Medtronic, Santa Rosa, California) (n  1,150) or
he Xience V everolimus-eluting stent (EES) (Abbott Vas-
ular, Santa Clara, California) (n  1,150). The Resolute
ES has the same cobalt chromium stent platform and drug
s the previous Endeavor ZES but features a different
olymer, allowing for a longer duration of drug release due
o its novel topcoat. Baseline characteristics were well
atched, but the EES group had a higher number of stents
sed per patient (2.0  1.3 vs. 1.9  1.2, p  0.02) and a
onger stent length per patient (37.0  26.5 mm vs. 34.4 
4.5 mm, p  0.02). The 12-month TLF rates were 8.2% in
he ZES group and 8.3% in the EES group (p for noninferi-
rity 0.01). Cardiac death (1.3% vs. 1.7%, p  0.61), target
essel myocardial infarction (4.2% vs. 4.1%, p  0.92), and
linically driven TLR (3.9% vs. 3.4%, p  0.50) were similar
or patients treated with ZES and EES. Of note, the 12-
onth rate of definite stent thrombosis was significantly higher
n the ZES arm (1.2% vs. 0.3%, p  0.01).
Although the increased rates of definite stent thrombosis
n the ZES arm despite the use of higher number and longer
ength of stents per patient in the EES arm could be a cause
or concern, the study was only powered for the primary end
oint, and definitive conclusions will require longer vollow-up in large trials that have sufficient statistical power
o detect differences in rates of stent thrombosis.
he NEVO RES-ELUTION I Trial
he NEVO RES-ELUTION I trial (5) enrolled a total of
94 patients with single de novo native coronary artery
esions randomized to treatment with the Nevo sirolimus-
luting stent (SES) (Cordis, Miami Lakes, Florida) or the
axus Liberté PES (Boston Scientific, Natick, Massachu-
etts). The Nevo SES features a cobalt chromium stent
latform with a biodegradable polymer that elutes sirolimus
rom reservoirs on the abluminal surface of the stent. The
rimary end point of in-stent late loss was significantly
ower at 6 months with Nevo SES than with PES (0.13 
.31 mm vs. 0.30  0.46 mm, p  0.01). Moreover, there
as a weak trend towards lower major adverse cardiac events
defined as death, myocardial infarction, or TLR) in the
evo SES compared with the PES group (6.1% vs. 10.8%,
 0.14) at 12-month follow-up. No cases of stent
hrombosis occurred in the Nevo SES group; 1 probable and
possible stent thrombosis occurred in the PES group up to
2-month follow-up.
The Nevo SES introduces a unique stent design with
romising results. Although the trial was not powered for
linical end points, the results for the Nevo SES suggest that
here are no differences in major adverse cardiac events
etween the 2 groups. Future comparisons against second-
eneration drug-eluting stents in larger groups of higher-
isk patients remain to be seen.
he ABSORB Cohort B Trial
he second phase of the ABSORB (A Bioabsorbable
verolimus-Eluting Coronary Stent System for Patients
ith Single De-Novo Coronary Artery Lesions) trial (Co-
ort B) (6) enrolled 101 patients from 12 centers (outside
he U.S.) treated with revision 1.1 of the everolimus-eluting
ioabsorbable vascular scaffold (BVS, Abbott Vascular).
ix-month results for the first 45 patients, with up to 2 de
ovo native coronary artery lesions 14 mm in length and
reference vessel diameter of 3.0 mm, were presented. The
esign of the BVS was modified to address the issue of
onsignificantly increased late recoil with the BVS revision
.0 compared with the Xience V EES (Abbott Vascular) (7)
nd incorporated device enhancements designed to improve
eliverability and vessel support. The revision 1.0 design of
he BVS was absorbed within 2 years after implantation;
lthough no long-term data on absorption of the revision
.1 design are currently available, it is expected to have a
imilar absorption profile (6). In the first 45 patients of
BSORB Cohort B, in-stent late loss was 0.19 mm at
-month angiographic follow-up. The 6-month major ad-
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884nfarction, or ischemia-driven TLR) was 4.4%. Further-
ore, no stent thrombosis had occurred at 6 months.
The ABSORB trial has shown that the theoretical aims
f the bioabsorbable stent are close to becoming a reality.
lthough this cohort implies safety of the new revision of
VS, the overall safety of these devices requires further
onfirmation in large future event-driven clinical trials.
he DEBIUT Trial
he DEBIUT (Drug-Eluting Balloon In Bifurcation Trial)
nvestigators randomized 120 patients with coronary bifur-
ation lesions in a 1:1:1 ratio to provisional T-stenting and
nal kissing balloons with a paclitaxel-eluting balloon
PEB) (Dior balloon, Eurocor, Bonn, Germany) and bare-
etal stent (BMS), standard balloon (STB) and PES, or
TB and BMS (8). The primary end point of side-branch
ate lumen loss did not significantly differ between the 3
reatment groups (PEBBMS: 0.04 mm, STBDES: 0.11
m, STBBMS: 0.10 mm). At 6-month follow-up, there
ere no deaths, and only 1 patient had stent thrombosis, in
he STBPES arm. Although a numerical reduction in
-month TLR was observed with the PEBBMS (12.5%)
nd STBPES (10.0%) arms compared with the
TBBMS arm (27.5%), this difference did not reach
tatistical significance.
Drug-eluting balloons offer a novel technique in attempts
o curb restenosis in complex lesion subsets. Although this
tudy did not reach statistical significance for reduction in
LR with PEB, the safety profile and 6-month clinical
rends pave the way for larger randomized trials with longer
ollow-up for definitive conclusions.
ummary
he 2010 SCAI and EuroPCR scientific sessions presented
ome new data on breaking clinical trials and established
ollow-up data on some previously initiated trials in inter-
entional cardiology, which have been summarized. Further letails on these studies can be accessed at the American
ollege of Cardiology’s Cardiosource website (9).
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